Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody‐associated vasculitis

• DOI: 10.1111/nep.12416
• Publication Date: 2015-02-06T08:19:36Z
• Authors: Lisa S Jeffs; Chen Au Peh; Matthew D Jose; Kylie Lange; Plinio R Hurtado
• Keywords: Adult; Male; Adolescent; 610; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; anti-neutrophil cytoplasmic antibody-associated vasculitis; Antibodies, Viral; vasculitis; Antibodies, Antineutrophil Cytoplasmic; Young Adult; 03 medical and health sciences; Influenza A Virus, H1N1 Subtype; 0302 clinical medicine; Influenza, Human; Humans; Prospective Studies; seroconversion; Aged; Aged, 80 and over; immunosuppression; Influenza A Virus, H3N2 Subtype; anti-neutrophil cytoplasmic antibody; Middle Aged; influenza vaccination; 3. Good health; Influenza B virus; Treatment Outcome; Influenza Vaccines; Female

This study evaluated the safety and efficacy of influenza vaccination in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.Thirty-one who were remission randomized to receive either a trivalent vaccine or no vaccine. Vaccine was assessed at 28 days. Patients followed for 6 months signs reactivation disease. In addition, 67 healthy individuals assess its potential triggering formation autoantibodies.Compared did not vaccine, vaccinated achieved effective responses all three antigens. There significant change levels antibody post-vaccination. disease activity compared non-vaccinated patients. Among individuals, we observe any level autoantibodies measured.This shows that administration vasculitis is both safe modestly efficacious.